Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Condition(s):Acute Lymphoblastic Leukemia; HepatotoxicityLast Updated:January 9, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Acute Lymphoblastic Leukemia; HepatotoxicityLast Updated:January 9, 2024Recruiting
Condition(s):Muscle LossLast Updated:August 17, 2021Completed
Condition(s):Hemodialysis ComplicationLast Updated:April 18, 2023Recruiting
Condition(s):Spinal Muscular AtrophyLast Updated:January 1, 2016Unknown status
Condition(s):Patient ComplianceLast Updated:October 30, 2019Unknown status
Condition(s):Disorder of Fatty Acid MetabolismLast Updated:December 25, 2014Completed
Condition(s):Compare Between the Serum Level of Lcarnitine in HIE Cases and TTNLast Updated:September 14, 2020Completed
Condition(s):Metabolic X Syndrome; Overweight; DyslipidemiasLast Updated:November 2, 2014Completed
Condition(s):MalnutritionLast Updated:March 7, 2024Completed
Condition(s):Diabetic Peripheral Neuropathic PainLast Updated:November 8, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.